We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Paychex (PAYX) Set to Report Q4 Earnings: What to Expect?
Read MoreHide Full Article
Paychex, Inc. (PAYX - Free Report) is scheduled to report fourth-quarter fiscal 2021 results on Jun 25, before market open.
Let's check out the expectations in detail.
Q4 Expectations
The Zacks Consensus Estimate for the company’s to-be-reported quarter’s revenues stands at $980.6 million, indicating an increase of 7.2% from the year-ago reported figure.
The consensus mark for Management Solutions revenues stands at $721 million, indicating growth of 8.9% from the year-ago reported number. Growth of the company’s client base and increased penetration of its suite of solutions, especially HR outsourcing, time and attendance, and retirement services; and solid growth from new services and product initiative offerings are likely to have aided the top line.
The consensus mark for Professional employer organization and Insurance Solutions revenues stands at $244 million, indicating growth of 7% from the year-ago reported number.
The consensus estimate for interest on funds held by clients’ revenues is pegged at $14.37 million, indicating 43.2% year-over-year decline. Lower average interest rates and realized gains are likely to have weighed on segmental revenues.
The consensus mark for earnings is pegged at 67 cents per share, indicating growth of 9.8% from the year-ago quarter’s reported figure.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Paychex this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Paychex has an Earnings ESP of 0.00% and a Zacks Rank #3.
Here are a few stocks from the broader Zacks Business Services sector that investors may consider, as our model shows that these have the right combination of elements to beat on earnings in their upcoming release.
S&P Global (SPGI - Free Report) has an Earnings ESP of +2.16% and a Zacks Rank #3.
Aptiv (APTV - Free Report) has an Earnings ESP of +1.38% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Paychex (PAYX) Set to Report Q4 Earnings: What to Expect?
Paychex, Inc. (PAYX - Free Report) is scheduled to report fourth-quarter fiscal 2021 results on Jun 25, before market open.
Let's check out the expectations in detail.
Q4 Expectations
The Zacks Consensus Estimate for the company’s to-be-reported quarter’s revenues stands at $980.6 million, indicating an increase of 7.2% from the year-ago reported figure.
The consensus mark for Management Solutions revenues stands at $721 million, indicating growth of 8.9% from the year-ago reported number. Growth of the company’s client base and increased penetration of its suite of solutions, especially HR outsourcing, time and attendance, and retirement services; and solid growth from new services and product initiative offerings are likely to have aided the top line.
The consensus mark for Professional employer organization and Insurance Solutions revenues stands at $244 million, indicating growth of 7% from the year-ago reported number.
The consensus estimate for interest on funds held by clients’ revenues is pegged at $14.37 million, indicating 43.2% year-over-year decline. Lower average interest rates and realized gains are likely to have weighed on segmental revenues.
The consensus mark for earnings is pegged at 67 cents per share, indicating growth of 9.8% from the year-ago quarter’s reported figure.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for Paychex this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Paychex has an Earnings ESP of 0.00% and a Zacks Rank #3.
Paychex, Inc. Price and EPS Surprise
Paychex, Inc. price-eps-surprise | Paychex, Inc. Quote
Stocks to Consider
Here are a few stocks from the broader Zacks Business Services sector that investors may consider, as our model shows that these have the right combination of elements to beat on earnings in their upcoming release.
ABM Industries (ABM - Free Report) has an Earnings ESP of +4.64% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
S&P Global (SPGI - Free Report) has an Earnings ESP of +2.16% and a Zacks Rank #3.
Aptiv (APTV - Free Report) has an Earnings ESP of +1.38% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>